Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Jaimie has a BS in Marketing Management from Coastal Carolina University. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Michael is Executive Vice President at Capstan Therapeutics. BioSpace's List Of The Top 5 Biggest VC Vampires In Biotech Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT. Kat Riesen is the VP, Finance at RA Ventures (RAVen). Sarah Reed is the General Counsel at RA Capital Management. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Prior to RA, Rob spent 21 years at the Broad Institute of MIT and Harvard, most recently as the Senior Director of Technology Development and a Principal Investigator. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. "Too old," said a man in his 70s. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. As the first and founding member of Kymeras scientific team, Jesse was responsible for building the companys industry-leading targeted protein degradation platform and pipeline, and he helped secure the companys Series A and B financings as well as a partnership with Vertex. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Harvey is a Controller at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). Les primary responsibility is to coordinate various technology related initiatives across the company. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. Erin Clutter is the Head of Graphics at RA Capital Management. In his Venture role, Mario is focusing on early-stage investment and company creation. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Previously, Derek covered solid tumor oncology landscapes. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Mario is a Venture Partner and Head of Vaccines at RA Capital. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Peter Kolchinsky - Managing Partner - CrunchBase He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Nadim Shohdy is an EIR at RA Capital. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Priscilla previously held a Senior Scientist role at Sanofi. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Prior to this role, Alyssa mapped a number of competitive landscapes of drugs and medical devices for disease indications and capabilities. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Le Ho is a Business Systems Analyst at RA Capital Management. Previously, Shan Shan covered Orphan Heme, Orphan GOF, Vaccines, and various Gene Therapies as a Senior Associate. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. He was Vice President of Merck business development and licensing where he led BD activities in the US (West Coast), Europe, and Asia Pacific region, as well as President of MRL Ventures where he led equity investing in early-stage therapeutics companies. Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Peter Kolchinsky Number of IPOs: 18. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Barrie's 1911 novel. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Peter Kolchinsky on Twitter Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. Before pursuing an M.B.A. at Harvard Business School, Michael received his M.D. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Laura is an Executive Assistant at RA Capital Management. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. Mike earned his MBA from the Darden Graduate School of Business Administration. All rights reserved. Megan has a BS in Microbiology & Cell Science from University of Florida. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Tim received his A.B. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Her primary responsibilities are to provide strategic administrative support and to assist the co founder in various external and internal projects She previously held Senior Executive Assistant roles at Genuity Science and Charles River Laboratories, and served as Director of Operations at Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Adam Rosenberg is an Advisor for RA Capital Management. Tess works on both public and private investments and serves on several company boards. Biohaven Closes Second Tranche Of Private Placement And Appoints Two Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. Priscilla has a B.S. Support. Peter Pan & Wendy Movie Review | Common Sense Media Raj holds a BA from Cornell University, where he majored in Chemistry. Lauras primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Harveys primary responsibility is to oversee all accounting related activities for the firm. In his most recent role as Entrepreneur In Residence and Head of Computation at RA Ventures (RAVen), Soumya Ray supported the creation of two RAVen-incubated newcos. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). She holds a BBA in Marketing from Loyola University Maryland. Rajeev Shah is a Managing Partner at RA Capital Management. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. Asia Pacific +65 6212 1000. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Tom is a Senior Operations Analyst at RA Capital Management. He held senior management positions at two successful start-up companies that were acquired and he has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Lucas Guevara is a Compliance Counsel at RA Capital Management. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. Phi Thach is an Executive Assistant at RA Capital Management. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Peter Kolchinsky | RA Capital Management Profile - TipRanks.com Founders GSAS Harvard Biotech Club Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn